ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0550

Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research

Kazuki Yoshida, Tianrun Cai, Lily G Bessette, Erin Kim, Su Been Lee, Luke E Zabotka, Alec Sun, Julianna M. Mastrorilli, Theresa A. Oduol, Jun Liu, Daniel Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA

Meeting: ACR Convergence 2022

Keywords: Administrative Data, Epidemiology, gout, Outcome measures, Uric Acid, Urate

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Abstracts: Exemplary Interprofessional Research

Session Type: Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no specific diagnosis code or unified treatment protocol for gout flares. We aimed to determine whether integrating concepts extracted from the narrative notes from the electronic health record (EHR) data using natural language processing (NLP) could improve the identification of gout flares for the purpose of comparative effectiveness research.

Methods: Using Medicare claims data (Parts A/B/D 2007-16) linked with EHR from two tertiary care centers, we selected individuals with age≥65 and ≥1 gout ICD-9 or 10 code who initiated the urate-lowering therapy (ULT). Patients were required to have ≥12 months with continuous enrollment (i.e., baseline period) before ULT initiation. The baseline period and on-treatment follow-up were segmented into 1-month units. We retrieved EHR notes for months with gout ICD codes in claims, and processed notes for NLP concepts related to gout using NLP. We selected a random sample of patients and reviewed each of their notes for the presence of acute gout flare based on the physician documentation of gout flare as the gold standard. Months containing 1+ notes with acute gout flares were considered months with events. We then used 60% of patients to train predictive models with LASSO using claims variables only, concepts only, and both combined. We evaluated the models by comparing the area under the curve (AUC) of ROCs in the 40% validation data and examined positive predictive value (PPV) at specificity thresholds of 85, 90, and 95%.

Results: We extracted and labeled 3,482 notes from 500 patients for the presence of acute gout flares, representing 839 months of follow-up time, and 280 months with gout flares. We used 93 claims variables and 84 EHR NLP concepts in LASSO. The claims-only model selected 20 variables (Table 1; e.g., steroids, colchicine, diabetes) with AUC 0.69 [95%CI 0.64,0.75] (Figure 1). The NLP concept-only model selected 17 (e.g., “gout”, “pain”, “arthralgia”) with AUC 0.69 [95%CI 0.63,0.75]. The combined model selected 32 claims variables (e.g., steroids, NSAIDs, colchicine) and 13 NLP concepts (e.g., “gout”, “pain”, “arthralgia”) with AUC 0.73 [95%CI 0.68,0.79]. The claims-only algorithm had a positive predictive value (PPV) of 0.64 and negative predictive value (NPV) of 0.71 at the specificity of 90%, whereas the combined algorithm had a PPV of 0.76 and NPV of 0.71 at the specificity of 95% (Table 2).

Conclusion: Although either claims variables alone or EHR NLP concepts alone achieved similar discrimination, the model with both claims and EHR variables resulted in a small improvement in the AUC. Compared to an existing rule-based claims algorithm (PPV 0.59-0.68; MacFarlane 2016 Pharmacoepi Drug Saf), our data-driven claims-only algorithm was comparable and our data-driven claims + NLP concept algorithm outperformed (PPV 0.76 at specificity 95%).

Supporting image 1

Table 1. Variables selected by LASSO.

Supporting image 2

Figure 1. Validation area under the curve (AUC) for each model.

Supporting image 3

Table 2. Performance of the claims-only and claims + NLP concept models at different specificity thresholds (85, 90, 95, 97%).


Disclosures: K. Yoshida, None; T. Cai, None; L. Bessette, None; E. Kim, None; S. Lee, None; L. Zabotka, None; A. Sun, None; J. Mastrorilli, None; T. Oduol, None; J. Liu, None; D. Solomon, None; K. Liao, None; S. Kim, Pfizer, AbbVie/Abbott, Roche, Bristol-Myers Squibb(BMS).

To cite this abstract in AMA style:

Yoshida K, Cai T, Bessette L, Kim E, Lee S, Zabotka L, Sun A, Mastrorilli J, Oduol T, Liu J, Solomon D, Liao K, Kim S. Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/improving-the-accuracy-of-automated-gout-flare-ascertainment-using-natural-language-processing-of-medical-records-and-linked-medicare-claims-data-for-real-world-comparative-effectiveness-research/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-the-accuracy-of-automated-gout-flare-ascertainment-using-natural-language-processing-of-medical-records-and-linked-medicare-claims-data-for-real-world-comparative-effectiveness-research/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology